Optical Imaging Platforms for Advanced Preclinical Modeling

Advanced in-life visualization of cancer development and progression

invivo-magnifyglass.png

"CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease.

Leveraging our industry expertise, CrownBio's global resources help customers answer the most challenging questions about human biology. We begin with the end insight to help you achieve your goals"

Dr Jean-Pierre Wery
CEO, Crown Bioscience Inc.

CrownBio provides non-invasive 2D and 3D bioluminescence and fluorescence optical imaging, for real-time longitudinal monitoring of tumor growth, progression, metastasis, and gene expression.

  • Optical imaging is a powerful translational screening tool, for maximizing scientific output and supporting the 3Rs.
  • Efficient and informative efficacy evaluation for different cancer stages, from primary lesions through to metastasis.
  • Validation across a broad range of cancer types at relevant organ and metastatic sites.
  • Applicable for both solid tumors and hematological cancers.
  • Available for both xenograft models in immunodeficient mice and syngeneic models in immunocompetent mice.
  • In-life imaging of multiple mice at multiple time points.
  • Bespoke bioluminescent model development available for unique cell lines.

Bioluminescent Syngeneic and Xenograft Models

CrownBio has validated a large panel of syngeneic models for immunotherapy research along with a panel of bioluminescent orthotopic and metastatic cell line derived xenograft models.

Bioluminescent imaging (BLI) of our models can be used to provide valuable disease information at different cancer stages, through orthotopic models to mimic primary lesions, to the imaging of both spontaneous and experimental metastases to replicate progression to late stage disease. Our imaging of cancer progression is performed using the in vivo imaging system IVIS® Spectrum CT, which is the industry’s most sensitive detection technology.

Table 1: CrownBio Bioluminescent Syngeneic Panel

Tissue

Cell Line

Model Type

Mouse bladder

MBT-2

Orthotopic (in development)

Mouse breast

4T1 Mammary fat pad with metastasis

EMT6

Mammary fat pad

Mouse liver

H22 Orthotopic
Hepa 1-6 Orthotopic

Mouse melanoma

B16-F10

Metastatic (intracardiac injection with bone metastasis, i.v. injection with lung metastasis), under refinement

Mouse pancreas

Pan02 Orthotopic

Mouse prostate

RM-1

Orthotopic (in development)


Table 2: CrownBio Bioluminescent Cell Line Derived Xenograft Panel

Tissue

Cell Line

Model Type

Solid Tumor Xenograft Models

Brain, GBM

U-87 MG

Orthotopic

Breast

MCF7 Mamary fat pad with metastasis

MDA-MB-231

Mamary fat pad with metastasis
Experimental metastatic (intracardiac injection with bone metastases, treatment with Taxotere® drives CNS metastases)

MDA-MB-361 Orthotopic (ongoing)
MDA-MB-468 Orthotopic (ongoing)
SK-BR-3 Orthotopic (ongoing)
T47D Orthotopic (ongoing)
ZR-75-1

Orthotopic
Experimental metastatic (intracardiac injection with bone metastases)

Liver, HCC

Hep 3B Orthotopic

Lung, NSCLC

A549

Orthotopic with metastasis
NCI-H2228

Orthotopic
Experimental metastatic (stereotactic intracranial implantation with CNS progression)

Ovarian

A2780 Peritoneal ascites

Prostate

PC-3M

Orthotopic with metastasis
Hemopoietic Xenograft Models

AML

MV-4-11

Systemic